中草药

日蟾蜍它灵通过PFKFB4介导的GSK-3β/mTOR信号通路诱导鼻咽癌细胞自噬

PDF下载

中草药 | 药理与临床 2026,57(19): 7651-7665

收起

中草药 |药理与临床 2026 , 57 (19) : 7651 -7665

日蟾蜍它灵通过PFKFB4介导的GSK-3β/mTOR信号通路诱导鼻咽癌细胞自噬

全屏

张乃宇¹, 慕岳峻², 孙欣¹, 张雪峰³, 冯晓飞³, 熊雪梅¹, 林海燕¹, 毕思学¹

作者信息

通讯作者:

毕思学

作者简介:

张乃宇: 张乃宇，女，硕士研究生，研究方向为中药抗肿瘤药理研究。E-mail:1226984985@qq.com

Gamabufotalin induces autophagy via PFKFB4-mediated GSK-3β/mTOR signaling pathway in nasopharyngeal carcinoma cells

ZHANG Naiyu¹, MU Yuejun², SUN Xin¹, ZHANG Xuefeng³, FENG Xiaofei³, XIONG Xuemei¹, LIN Haiyan¹, BI Sixue¹

Affiliations

doi: 10.7501j.issn.0253-2670.2026.19.013

文章导航

摘要

收起

目的研究日蟾蜍它灵（gamabufotalin，CS-6）对鼻咽癌细胞增殖的影响，从细胞周期阻滞和自噬探讨CS-6抑制鼻咽癌细胞增殖的机制。方法通过CCK-8实验、克隆形成实验检测CS-6对HK-1和5-8F细胞的增殖抑制作用；使用流式细胞仪检测CS-6对HK-1和5-8F细胞周期分布和凋亡的影响；采用Western blotting检测细胞周期蛋白B1（Cyclin B1）和周期蛋白依赖性激酶1（cyclin dependent protein kinase 1，CDK1）的表达；采用转录组测序技术筛选CS-6作用于细胞后的差异表达基因，IPA软件分析差异表达基因的富集通路；采用透射电镜观察CS-6作用于细胞后自噬体的超微结构；采用Western blotting检测微管相关蛋白轻链3（microtubule-associated protein light chain 3，LC3）、p62、糖原合成酶激酶-3β（glycogen synthase kinase-3β，GSK-3β）/哺乳动物雷帕霉素靶蛋白（mammalian target of rapamycin，mTOR）通路相关蛋白表达；通过瞬时转染mCherry-EGFP-LC3质粒后，使用激光共聚焦显微镜观察CS-6作用于细胞后自噬通量的变化。为了研究PFKFB4在CS-6诱导鼻咽癌细胞增殖、周期阻滞及自噬中的作用，HK-1和5-8F细胞转染PFKFB4质粒后，采用qRT-PCR和Western blotting检测6-磷酸果糖-2-激酶/果糖-2,6-二磷酸酶-4（6-phosphofructo-2-kinase/fructose-2,6-biphosphatase 4，PFKFB4）的表达，检测细胞存活率、集落形成、自噬通量、细胞周期和自噬相关蛋白表达的变化。体内建立鼻咽癌移植瘤小鼠模型，给予CS-6干预后，测定肿瘤体积和质量，采用苏木素-伊红染色观察肿瘤、肝、肾组织病理变化，采用免疫组化法检测肿瘤组织Ki67表达，采用Western blotting检测肿瘤组织中LC3、p62、Cyclin B1、CDK1、p-mTOR、PFKFB4、p-GSK-3β蛋白表达。结果 CS-6作用于细胞48 h后，能够显著抑制HK-1和5-8F细胞的增殖（P＜0.05、0.001），其半数抑制浓度分别为8.684、14.320 nmol/L；CS-6引起HK-1和5-8F细胞发生明显的G₂/M期阻滞（P＜0.05、0.01），同时增加Cyclin B1和CDK1的蛋白表达（P＜0.05、0.01、0.001）；CS-6在48 h处理条件下未诱导HK-1和5-8F细胞发生凋亡。CS-6显著降低PFKFB4的mRNA及蛋白表达（P＜0.05、0.01、0.001），在细胞内观察到自噬典型的双层膜结构及自噬溶酶体，上调LC3-II/I以及下调p62的蛋白表达（P＜0.05、0.01、0.001），促进自噬体与溶酶体的融合。过表达PFKFB4能部分逆转CS-6对细胞增殖的抑制以及对细胞周期、自噬相关蛋白表达的调控作用（P＜0.05、0.01、0.001），并使自噬小体和溶酶体的融合受阻。CS-6显著增加p-GSK-3β表达并抑制p-mTOR的表达（P＜0.05、0.01、0.001）；过表达PFKFB4可部分逆转CS-6对p-GSK-3β和p-mTOR的调控作用（P＜0.05、0.01）。体内实验中，CS-6显著抑制荷瘤小鼠肿瘤生长（P＜0.001），诱导肿瘤组织发生病理损伤，抑制肿瘤细胞增殖（P＜0.001），上调肿瘤组织中LC3-II/I、p-GSK3β表达并下调p62表达（P＜0.001），下调p-mTOR、PFKFB4、Cyclin B1和CDK1的蛋白表达（P＜0.01、0.001），且对肝肾组织无影响。结论 CS-6通过下调PFKFB4，进而调控GSK-3β/mTOR信号通路，激活自噬及细胞周期过程，从而发挥抗鼻咽癌作用。

关键词

鼻咽癌 / 日蟾蜍它灵 / PFKFB4 / 细胞自噬 / GSK-3β/mTOR信号通路

Abstract

收起

Objective To study the effect of gamabufotalin (CS-6) on the proliferation of nasopharyngeal carcinoma cells, and explore the mechanism by which CS-6 inhibits nasopharyngeal carcinoma cell proliferation through cell cycle arrest and autophagy. Methods The inhibitory effect of CS-6 on the proliferation of HK-1 and 5-8F cells was detected through CCK-8 assay and colony formation assay. Flow cytometry was used to detect the effect of CS-6 on the cell cycle distribution and apoptosis of HK-1 and 5-8F cells. Western blotting was used to detect the expressions of Cyclin B1 and cyclin dependent protein kinase 1 (CDK1). Transcriptome sequencing was used to screen for differentially expressed genes after CS-6 treatment, and IPA software was used to analyze the enrichment pathways of differentially expressed genes. The ultrastructure of autophagosomes after CS-6 acts on cells was observed using transmission electron microscopy. Western blotting was used to detect the expressions of microtubule associated protein light chain 3 (LC3), p62, and glycogen synthase kinase-3β (GSK-3β)/mammalian target of rapamycin (mTOR) pathway related proteins. After transient transfection of mCherry-EGFP-LC3 plasmid, the changes in autophagy flux of cells treated with CS-6 were observed using laser confocal microscopy. In order to investigate the effect of PFKFB4 on CS-6-induced proliferation, cell cycle arrest and autophagy of nasopharyngeal carcinoma cells, HK-1 and 5-8F cells were transfected with PFKFB4 plasmid, qRT-PCR and Western blotting were used to detect the expression of 6-phosphofructo-2-kinase/fructose-2,6-biphosphatase-4 (PFKFB4), as well as changes in cell survival rate, colony formation, autophagy flux, cell cycle and autophagy related protein expressions. A mouse model of nasopharyngeal carcinoma transplantation in vivo was established, after CS-6 administration, tumor volume and weight were measured, pathological changes in tumor, liver and kidney tissues were observed using hematoxylin-eosin staining, Ki67 expression in tumor tissues was detected using immunohistochemistry, LC3, p62, Cyclin B1, CDK1, p-mTOR, PFKFB4 and p-GSK-3β protein expressions in tumor tissues were detected using Western blotting. Results After 48 h of treatment, CS-6 significantly inhibited the proliferation of HK-1 and 5-8F cells (P < 0.05, 0.001), with half-maximal inhibitory concentrations of 8.684 and 14.320 nmol/L, respectively. CS-6 caused significant G₂/M phase arrest in HK-1 and 5-8F cells (P < 0.05, 0.01), while increasing protein expressions of Cyclin B1 and CDK1 (P < 0.05, 0.01, 0.001). CS-6 did not induce apoptosis in HK-1 and 5-8F cells under treatment conditions of 48 h. CS-6 significantly reduced the mRNA and protein expressions of PFKFB4 (P < 0.05, 0.01, 0.001), typical double-membrane autophagosomes and autolysosomes were observed in the cells, CS-6 upregulated LC3-II/I and downregulated p62 protein expressions (P < 0.05, 0.01, 0.001), promoted the fusion of autophagosomes and lysosomes. Overexpression of PFKFB4 could partially reverse the inhibitory effect of CS-6 on cell proliferation and regulate the expressions of cell cycle and autophagy related proteins (P < 0.05, 0.01, 0.001), and inhibit the fusion of autophagosomes and lysosomes. CS-6 significantly increased the expression of p-GSK-3β and inhibited the expression of p-mTOR (P < 0.05, 0.01, 0.001). Overexpression of PFKFB4 could partially reverse the regulatory effects of CS-6 on p-GSK-3β and p-mTOR (P < 0.05, 0.01). In vivo, CS-6 significantly inhibited tumor growth in tumor bearing mice (P < 0.001), induced pathological damage to tumor tissue, inhibited tumor cell proliferation (P < 0.001), upregulated LC3-II/I, p-GSK-3β expressions and downregulated p62 expression in tumor tissue (P < 0.001), downregulated protein expressions of p-mTOR, PFKFB4, Cyclin B1 and CDK1 (P < 0.01, 0.001), and had no effect on liver and kidney tissues. Conclusion CS-6 exerts an anti-nasopharyngeal carcinoma effect by downregulating PFKFB4, thereby regulating GSK-3β/mTOR signaling pathway and inducing autophagy and cell-cycle arrest.

Key words

nasopharyngeal carcinoma / gamabufotalin / PFKFB4 / autophagy / GSK-3β/mTOR signaling pathway

引用本文

张乃宇, 慕岳峻, 孙欣, 张雪峰, 冯晓飞, 熊雪梅, 林海燕, 毕思学. 日蟾蜍它灵通过PFKFB4介导的GSK-3β/mTOR信号通路诱导鼻咽癌细胞自噬. 中草药, 2026 , 57 (19) : 7651 -7665 . DOI: 10.7501j.issn.0253-2670.2026.19.013

ZHANG Naiyu, MU Yuejun, SUN Xin, ZHANG Xuefeng, FENG Xiaofei, XIONG Xuemei, LIN Haiyan, BI Sixue. Gamabufotalin induces autophagy via PFKFB4-mediated GSK-3β/mTOR signaling pathway in nasopharyngeal carcinoma cells[J]. Chinese Traditional and Herbal Drugs, 2026 , 57 (19) : 7651 -7665 . DOI: 10.7501j.issn.0253-2670.2026.19.013

基金

收起

山东省自然科学基金面上项目 (ZR2024MH059); 滨州医学院中医药学科融合科技计划专项项目 (2024YYKJ12); 国家自然科学基金青年基金项目 (82104463); 山东省自然科学基金青年基金项目 (ZR202103060169)

参考文献

收起

文献

收起

参考文献引证文献

排序方式：

Chen Y P, Chan A T C, Le Q T, et al. Nasopharyngeal carcinoma [J]. Lancet, 2019, 394(10192): 64-80.
Carvajal F, Luyo G, Veloso J, et al. Advances in nasopharyngeal carcinoma treatment: Induction chemotherapy and concomitant radio-chemotherapy [J]. Rev Med Chil, 2023, 151(9): 1221-1232.
Lee H M, Okuda K S, González F E, et al. Current perspectives on nasopharyngeal carcinoma [M] //Rhim J S, Dritschilo A, Kremer R. Human Cell Transformation. Cham: Springer International Publishing, 2019: 11-34.
Su Z Y, Siak P Y, Lwin Y Y, et al. Epidemiology of nasopharyngeal carcinoma: Current insights and future outlook [J]. Cancer Metastasis Rev, 2024, 43(3): 919-939.
Zeng C L, Qiao M C, Chen Y H, et al. EBV-positive glycoproteins associated with nasopharyngeal carcinoma [J]. Pathol Res Pract, 2024, 260: 155427.
Liu Q Q, Wang H Y, Chen Z, et al. Global, regional, and national epidemiology of nasopharyngeal carcinoma in middle-aged and elderly patients from 1990 to 2021[J]. Ageing Res Rev, 2025, 104: 102613.
Chua M L, Sun Y, Supiot S. Advances in nasopharyngeal carcinoma-“West meets East” [J]. Br J Radiol, 2019, 92(1102): 20199004.
Tang L L, Chen Y P, Chen C B, et al. The Chinese Society of Clinical Oncology (CSCO) clinical guidelines for the diagnosis and treatment of nasopharyngeal carcinoma [J]. Cancer Commun, 2021, 41(11): 1195-1227.
Cai M Y, Wang Y F, Ma H R, et al. Advances and challenges in immunotherapy for locally advanced nasopharyngeal carcinoma [J]. Cancer Treat Rev, 2024, 131: 102840.
Juarez-Vignon Whaley J J, Afkhami M, Onyshchenko M, et al. Recurrent/metastatic nasopharyngeal carcinoma treatment from present to future: Where are we and where are we heading? [J]. Curr Treat Options Oncol, 2023, 24(9): 1138-1166.
Tang L L, Chen L, Xu G Q, et al. Reduced-volume radiotherapy versus conventional-volume radiotherapy after induction chemotherapy in nasopharyngeal carcinoma: An open-label, noninferiority, multicenter, randomized phase 3 trial [J]. CA Cancer J Clin, 2025, 75(3): 203-215.
安雪菁, 崔齐晓, 赵盈, 等. 蟾蜍它灵对人头颈部鳞状细胞癌的影响及作用机制[J]. 中草药, 2026, 57(4): 1325-1335.
Thompson H J, Lutsiv T. Natural products in precision oncology: Plant-based small molecule inhibitors of protein kinases for cancer chemoprevention [J]. Nutrients, 2023, 15(5): 1192.
Liu L, Shi D, Xia Z Y, et al. Gamabufotalin induces apoptosis and cytoprotective autophagy through the mTOR signaling pathway in hepatocellular carcinoma [J]. J Nat Prod, 2023, 86(4): 966-978.
Ma K, Zhang C, Li W Y. Gamabufotalin suppressed osteosarcoma stem cells through the TGF-β/periostin/PI3K/Akt pathway [J]. Chem Biol Interact, 2020, 331: 109275.
Yuan B, Shimada R, Xu K, et al. Multiple cytotoxic effects of gamabufotalin against human glioblastoma cell line U-87[J]. Chem Biol Interact, 2019, 314: 108849.
Kotowski K, Rosik J, Machaj F, et al. Role of PFKFB3 and PFKFB4 in cancer: Genetic basis, impact on disease development/progression, and potential as therapeutic targets [J]. Cancers, 2021, 13(4): 909.
Ros S, Flöter J, Kaymak I, et al. 6-Phosphofructo-2-kinase/fructose-2,6-biphosphatase 4 is essential for p53-null cancer cells [J]. Oncogene, 2017, 36(23): 3287-3299.
Chen S T, Han J S, Wang W, et al. Expression and prognostic analysis of PFKFB4 in oral squamous cell carcinoma [J]. Cell Mol Biol, 2024, 70(7): 193-199.
Zhou S, Liu Y, Zhang N, et al. Glycolytic enzyme PFKFB4 governs lipolysis by promoting de novo lipogenesis to drive the progression of hepatocellular carcinoma [J]. Cancer Lett, 2025, 626: 217774.
Wang T, Wang X T, Zheng X L, et al. Overexpression of SLC2A1, ALDOC, and PFKFB4 in the glycolysis pathway drives strong drug resistance in 3D HeLa tumor cell spheroids [J]. Biotechnol J, 2024, 19(9): e2400163.
Liu Y Z, Shi Q L, Liu Y F, et al. Fibrillarin reprograms glucose metabolism by driving the enhancer-mediated transcription of PFKFB4 in liver cancer [J]. Cancer Lett, 2024, 602: 217190.
Zhang R Q, Zhang Q, Deng F, et al. Potential applications of PFKFB in cancer treatment strategies [J]. Int J Biol Macromol, 2025, 320: 145860.
Jalal S, Zhang T, Deng J, et al. β-Elemene isopropanolamine derivative LXX-8250 induces apoptosis through impairing autophagic flux via PFKFB4 repression in melanoma cells [J]. Front Pharmacol, 2022, 13: 900973.
Schleicher S M, Moretti L, Varki V, et al. Progress in the unraveling of the endoplasmic reticulum stress/autophagy pathway and cancer: Implications for future therapeutic approaches [J]. Drug Resist Updat, 2010, 13(3): 79-86.
Moosavi M A, Djavaheri-Mergny M. Exploring the complex link between autophagy, regulated cell death, and cell fate pathways in cancer pathogenesis and therapy [J]. Cells, 2023, 12(3): 498.
Wang Y H, Chen B C, Xiao M, et al. Brucea javanica oil emulsion promotes autophagy in ovarian cancer cells through the miR-8485/LAMTOR3/mTOR/ATG13 signaling axis [J]. Front Pharmacol, 2022, 13: 935155.
Azoulay-Alfaguter I, Elya R, Avrahami L, et al. Combined regulation of mTORC1 and lysosomal acidification by GSK-3 suppresses autophagy and contributes to cancer cell growth [J]. Oncogene, 2015, 34(35): 4613-4623.
Fan J L, Liu B, Long Y, et al. Sequentially-targeted biomimetic nano drug system for triple-negative breast cancer ablation and lung metastasis inhibition [J]. Acta Biomater, 2020, 113: 554-569.
Yu Z L, Guo W, Ma X C, et al. Gamabufotalin, a bufadienolide compound from toad venom, suppresses COX-2 expression through targeting IKKβ/NF-κB signaling pathway in lung cancer cells [J]. Mol Cancer, 2014, 13(1): 203.
Gao R F, Liu Y H, Li D, et al. PFKFB4 promotes breast cancer metastasis via induction of hyaluronan production in a p38-dependent manner [J]. Cell Physiol Biochem, 2018, 50(6): 2108-2123.
Zhang P F, Tao W W, Lu C, et al. Bruceine A induces cell growth inhibition and apoptosis through PFKFB4/GSK3β signaling in pancreatic cancer [J]. Pharmacol Res, 2021, 169: 105658.
Cai Y C, Yang H, Shan H B, et al. PFKFB4 overexpression facilitates proliferation by promoting the G1/S transition and is associated with a poor prognosis in triple-negative breast cancer [J]. Dis Markers, 2021, 2021: 8824589.
Mizushima N, Komatsu M. Autophagy: Renovation of cells and tissues [J]. Cell, 2011, 147(4): 728-741.
Liu X C, Meng L, Li X, et al. Regulation of FN1 degradation by the p62/SQSTM1-dependent autophagy-lysosome pathway in HNSCC [J]. Int J Oral Sci, 2020, 12(1): 34.
Lamark T, Svenning S, Johansen T. Regulation of selective autophagy: The p62/SQSTM1 paradigm [J]. Essays Biochem, 2017, 61(6): 609-624.
Amaravadi R K, Kimmelman A C, Debnath J. Targeting autophagy in cancer: Recent advances and future directions [J]. Cancer Discov, 2019, 9(9): 1167-1181.
Mancinelli R, Carpino G, Petrungaro S, et al. Multifaceted roles of GSK-3 in cancer and autophagy-related diseases [J]. Oxid Med Cell Longev, 2017, 2017: 4629495.
Zhang Y J, Jiang L, Su P F, et al. Urolithin A suppresses tumor progression and induces autophagy in gastric cancer via the PI3K/Akt/mTOR pathway [J]. Drug Dev Res, 2023, 84(2): 172-184.
Yang J L, Pi C C, Wang G H. Inhibition of PI3K/Akt/mTOR pathway by apigenin induces apoptosis and autophagy in hepatocellular carcinoma cells [J]. Biomed Pharmacother, 2018, 103: 699-707.
Strohecker A M, Joshi S, Possemato R, et al. Identification of 6-phosphofructo-2-kinase/fructose-2,6-bisphosphatase as a novel autophagy regulator by high content shRNA screening [J]. Oncogene, 2015, 34(45): 5662-5676.
Zhou Y, Fan Y F, Qiu B Z, et al. Effect of PFKFB4 on the prognosis and immune regulation of NSCLC and its mechanism [J]. Int J Gen Med, 2022, 15: 6341-6353.
Wang Q Y, Zeng F R, Sun Y Q, et al. Etk interaction with PFKFB4 modulates chemoresistance of small-cell lung cancer by regulating autophagy [J]. Clin Cancer Res, 2018, 24(4): 950-962.
Senapati P K, Mahapatra K K, Singh A, et al. mTOR inhibitors in targeting autophagy and autophagy-associated signaling for cancer cell death and therapy [J]. Biochim Biophys Acta Rev Cancer, 2025, 1880(3): 189342.
Li J Y, Zhang D, Wang S H, et al. Baicalein induces apoptosis by inhibiting the glutamine-mTOR metabolic pathway in lung cancer [J]. J Adv Res, 2025, 68: 341-357.
Hossain M T, Hossain M A. Targeting mTOR kinase for cancer treatment: A comprehensive review with clinical insights [J]. Drug Dev Res, 2025, 86(7): e70167.
Piazza F, Manni S, Tubi L Q, et al. Glycogen synthase kinase-3 regulates multiple myeloma cell growth and bortezomib-induced cell death [J]. BMC Cancer, 2010, 10: 526.
Li G Y, Wu F M, Lei F, et al. MARCH5 promotes cardiac hypertrophy by regulating Akt/mTOR/GSK-3β/GATA4 signalling pathway [J]. J Cell Mol Med, 2025, 29(15): e70735.
Park C H, Lee B H, Ahn S G, et al. Serine 9 and tyrosine 216 phosphorylation of GSK-3β differentially regulates autophagy in acquired cadmium resistance [J]. Toxicol Sci, 2013, 135(2): 380-389.
Beurel E, Grieco S F, Jope R S. Glycogen synthase kinase-3(GSK3): Regulation, actions, and diseases [J]. Pharmacol Ther, 2015, 148: 114-131.

2026年第57卷第19期

PDF下载

引用本文

BibTeX

文章信息

doi: 10.7501j.issn.0253-2670.2026.19.013

接收时间：2026-02-19
首发时间：2026-10-29

补充材料

相关文章

文章信息

作者

出版历史

收稿日期：2026-02-19

基金

作者信息

参考文献

分享链接

https://castjournals.cast.org.cn/joweb/zcy/CN/10.7501j.issn.0253-2670.2026.19.013

分享至

全文二维码

扫描看全文

引用本文

BibTeX

本文的引用情况

2种不同金属材料的力学参数

科 Family	属数 Number of genus	种数 Number of species	占总种数比例 Percentage of total species (%)	属 Genus	种数 Number of species	占总种数比例 Percentage of total species (%)
鹅膏菌科Amanitaceae	2	11	5.26	鹅膏菌属 Amanita	10	4.78
小菇科 Mycenaceae	2	12	5.74	丝盖伞属 Inocybe	5	2.39
多孔菌科 Polyporaceae	8	14	6.70	蜡蘑属 Laccaria	5	2.39
红菇科 Russulaceae	3	23	11.00	小皮伞属 Marasmius	6	2.87
				小菇属 Mycena	11	5.26
				光柄菇属 Pluteus	5	2.39
				红菇属 Russula	17	8.13
				栓菌属 Trametes	5	2.39

关闭全屏

BibTeX
EndNote
RefWorks
TxT